Abivax Shares Surge 36% Amid Promising Trial Data for Ulcerative Colitis Treatment
Abivax shares jump 36 as new trial – A French biotechnology firm based in Paris, Abivax, experienced a significant 36% rise in its stock price on Tuesday following the release of updated trial results for its experimental drug, obefazimod. The company, which specializes in developing therapies for chronic inflammatory conditions, reported positive outcomes from the maintenance phase of its Phase 3 ABTECT trial, which has reignited investor confidence. The findings suggest that the oral treatment could offer meaningful benefits for adults with moderate to severe ulcerative colitis, particularly those who had not responded to prior treatments.
Positive Trial Outcomes Highlight Potential for Long-Term Management
The latest data from the Phase 3 ABTECT trial’s maintenance phase revealed that 37.2% of patients who had not achieved remission during the initial treatment phase entered clinical remission after 44 weeks. This means their symptoms were largely alleviated, marking a substantial improvement for those with persistent disease. Additionally, 34.5% of participants demonstrated healing of the intestinal lining, a key indicator of the drug’s efficacy. For patients whose condition relapsed after initial improvement, the study indicated that increasing the dosage to 50 mg resulted in a 45.5% remission rate, offering hope for better disease control in challenging cases.
The results come after a dramatic 44% drop in Abivax shares on June 2, when Phase 3 safety data initially raised concerns. However, the company has since clarified that the expanded safety analysis showed cancer rates remained consistent with historical averages observed in patients with ulcerative colitis. This reassurance has helped stabilize the stock, which climbed to €113.30 in Paris on Tuesday afternoon, reflecting renewed optimism.
Safety Analysis Reinforces Drug’s Profile
According to combined safety data from Phase 2 and Phase 3 trials, the risk of cancer excluding non-melanoma skin cancer was found to be 0.35 and 0.64 cases per 100 patient-years in the standard and 50 mg dosage groups, respectively. Non-melanoma skin cancer rates were similarly reported at 0.59 and 0.64 cases per 100 patient-years. These figures, which represent the equivalent of 1,704 years of patient exposure, indicate that the drug’s safety profile remains stable and does not introduce new risks. The company emphasized that no unexpected safety signals were detected, a critical point for regulatory approval.
Chief Executive Marc de Garidel highlighted the significance of the findings in a statement, stating,
“The expanded cumulative safety data further strengthens our confidence in the long-term safety profile of obefazimod and reinforces the favourable benefit-risk profile for our programme as we prepare for our planned NDA submission later this year.”
This confidence is bolstered by the drug’s ability to address both symptom management and structural healing, which could position it as a transformative option in ulcerative colitis treatment.
Path to FDA Approval and Broader Therapeutic Applications
Abivax confirmed that it is on track to submit a New Drug Application (NDA) for obefazimod to the U.S. Food and Drug Administration (FDA) by the end of 2026. The NDA submission is a pivotal step toward potential market entry, which could have significant implications for patients and investors. The company is also exploring the drug’s use in treating Crohn’s disease, another inflammatory bowel condition, which may expand its commercial reach beyond ulcerative colitis.
The positive Phase 3 results have not only revived interest in obefazimod but also opened the door for further clinical studies. Mid-stage Phase 2 trial results for Crohn’s disease are anticipated in mid-2027, providing additional insights into the drug’s versatility. Analysts are closely monitoring these developments, as the success of obefazimod could redefine treatment paradigms for inflammatory diseases. The drug’s oral formulation is particularly notable, as it offers a more convenient alternative to injectable therapies currently in use.
Despite the recent share fluctuations, Abivax’s ability to present balanced data—showing both efficacy and safety—has restored credibility. The company’s resilience in navigating trial challenges underscores its commitment to advancing innovative treatments. Investors are now eyeing the fourth quarter of 2026 as a potential turning point, with the NDA submission serving as a catalyst for future growth. The positive outcomes from the ABTECT trial, combined with the safety analysis, present a compelling case for obefazimod’s role in the pharmaceutical landscape.
Implications for the Inflammatory Bowel Disease Market
Ulcerative colitis is a chronic condition that affects millions globally, with current treatments often requiring long-term management. Obefazimod’s dual ability to reduce symptoms and promote bowel healing could address unmet needs, particularly for patients who experience treatment failure. The 45.5% remission rate among those whose disease relapsed highlights the drug’s potential to provide sustained therapeutic benefits, a factor that may differentiate it from existing options.
With the NDA submission looming, Abivax is positioning itself as a key player in the IBD market. The company’s focus on oral medications aligns with a growing trend toward patient-friendly delivery methods, which can improve adherence and quality of life. The Phase 3 trial’s maintenance phase data is especially important, as it demonstrates long-term effectiveness, a crucial criterion for regulatory approval. This success could also accelerate the development timeline for Crohn’s disease applications, expanding the drug’s therapeutic potential.
The market response to Abivax’s updated findings underscores the importance of continuous clinical evaluation in drug development. While the initial safety data had caused a sharp decline, the subsequent analysis has shown that the drug’s risks are manageable, and its benefits outweigh potential concerns. As the company moves closer to FDA submission, the focus will shift to real-world implementation and long-term patient outcomes. The data also sets a foundation for future research, including the exploration of obefazimod in other inflammatory conditions.
Abivax’s journey reflects the dynamic nature of biotechnology, where progress and setbacks often occur in close succession. The 36% share increase on Tuesday signals a shift in investor sentiment, with stakeholders now looking beyond short-term challenges to the drug’s broader impact. The company’s ability to adapt and communicate its findings effectively has been critical in maintaining momentum. As obefazimod nears regulatory approval, it may become a cornerstone of treatment for ulcerative colitis, offering new hope to patients and driving the company’s growth trajectory.
